Social media

Weight loss alone no longer defines success in obesity trials. With new treatments like GLP-1s showing both fat and muscle loss, researchers are rethinking what meaningful improvement really means. To do so, they are tur...

Throughout Breast Cancer Awareness Month, our colleagues across global offices came together to support this important cause through a series of impactful initiatives, including awareness walks, educational workshops, an...

GLP-1 receptor agonists have established compelling evidence for the commercial value of multi-indication drug development beyond obesity. Conventional paradigms for drug development must shift in order to adapt to multi...

Smarter oversight starts with smarter tools. ICON’s latest blog shows how tech enables agile, risk-based quality management in clinical trials. Explore the future of RBQM: https://ow.ly/wrH550XgO1g

Smarter oversight starts with smarter tools. ICON’s latest blog shows how tech enables agile, risk-based quality management in clinical trials. Explore the future of RBQM: https://ow.ly/4PG250XgO1e

October is intimate partner violence awareness month (IPV). IPV affects millions globally, yet its impact on clinical trial participation and outcomes remains largely unexamined. As the industry continues to advance equ...

October is intimate partner violence awareness month (IPV). IPV affects millions globally, yet its impact on clinical trial participation and outcomes remains largely unexamined. As the industry continues to advance equ...

Latest issue out now. Keep up to date on the latest changes with ICON’s Regulatory Intelligence Newsletter. Join thousands of subscribers who have discovered the convenience of this free monthly publication by signing u...

Latest issue out now. Keep up to date on the latest changes in the world of pharma, biotech and medical device clinical trial regulation with ICON’s Regulatory Intelligence Newsletter. Join thousands of subscribers who...

New research shows that clinical trials with digital endpoints can be completed 3 to 5 months faster than those without. This can be a difference worth millions. But the benefits of leveraging digital don’t end there. R...

ICON brings a comprehensive approach to obesity asset development, from imaging and diagnostics to adjudication strategies, device experience, and vendor solutions. Visit us at Obesity Week, Nov 4-7 at booth 520 to explo...

ICON leverages real-world evidence to uncover prescriber behavior, payer influence, and patient needs by identifying key subpopulations and quantifying therapeutic impact to build stronger value propositions. Arrange a t...